Evidence map›Paper›PMID 29978597›Full record

Trial reportAlimentary pharmacology & therapeutics2018

Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition.

Y Wouters, M Theilla, P Singer, S Tribler, P B Jeppesen, L Pironi, L Vinter-Jensen, H H Rasmussen, F Rahman, G J A Wanten

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alimentary pharmacology & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01826526 (Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
10.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01826526 nacompletednot on this map

Taurolidine 2% Catheter Locking to Prevent Catheter-related Bloodstream Infections in Patients on Home Parenteral Nutrition With a High Infection Risk and Those With a New Central Venous Access Device

TypeinterventionalSponsorGeert WantenRan2013 to 2016Enrolled105ConditionsCatheter Related Blood Stream InfectionsArmsTauroSept®
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. [Prevention and treatment strategies for intestinal failure-associated liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Pharmaceutical Aspects of Artificial Nutrition.Journal of clinical medicine · 2019
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Y WoutersIntestinal Failure Unit, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.ORCID 0000-0002-5822-0255
M TheillaGeneral Intensive Care Department, Rabin Medical Centre, Beilinson Hospital and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
P SingerGeneral Intensive Care Department, Rabin Medical Centre, Beilinson Hospital and Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
S TriblerDepartment of Medical Gastroenterology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
P B JeppesenDepartment of Medical Gastroenterology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
L PironiCentre for Chronic Intestinal Failure, Department of Medical and Surgical Science, University of Bologna, Bologna, Italy.
L Vinter-JensenDepartment of Gastroenterology, Centre for Nutrition and Bowel Disease, Aalborg University Hospital, Aalborg, Denmark.
H H RasmussenDepartment of Gastroenterology, Centre for Nutrition and Bowel Disease, Aalborg University Hospital, Aalborg, Denmark.
F RahmanDepartment of Gastroenterology, University College London Hospital, London, UK.
G J A WantenIntestinal Failure Unit, Department of Gastroenterology and Hepatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Aalborg University Hospital · DKCopenhagen University Hospital · DKRadboud University Nijmegen · NLTel Aviv University · ILUniversity College Hospital · GBUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe catheter lock solutions 2% taurolidine and 0.9% saline are both used to prevent catheter-related bloodstream infections (CRBSIs) in home parenteral nutrition patients.

aimsTo compare the effectiveness and safety of taurolidine and saline.

methodsThis multicentre double-blinded trial randomly assigned home parenteral nutrition patients to use either 2% taurolidine or 0.9% saline for 1 year. Patients were stratified in a new catheter group and a pre-existing catheter group. Primary outcome was the rate of CRBSIs/1000 catheter days in the new catheter group and pre-existing catheter group, separately.

resultsWe randomised 105 patients, of which 102 were analysed as modified intention-to-treat population. In the new catheter group, rates of CRBSIs/1000 catheter days were 0.29 and 1.49 in the taurolidine and saline arm respectively (relative risk, 0.20; 95% CI, 0.04-0.71; P = 0.009). In the pre-existing catheter group, rates of CRBSIs/1000 catheter days were 0.39 and 1.32 in the taurolidine and saline arm respectively (relative risk, 0.30; 95% CI, 0.03-1.82; P = 0.25). Excluding one outlier patient in the taurolidine arm, mean costs per patient were $1865 for taurolidine and $4454 for saline (P = 0.03). Drug-related adverse events were rare and generally mild.

conclusionsIn the new catheter group, taurolidine showed a clear decrease in CRBSI rate. In the pre-existing catheter group, no superiority of taurolidine could be demonstrated, most likely due to underpowering. Overall, taurolidine reduced the risk for CRBSIs by more than four times. Given its favourable safety and cost profile, taurolidine locking should be considered as an additional strategy to prevent CRBSIs.

trial registrationClinicaltrials.gov, identifier: NCT01826526.

Indexed as

AdultAgedBacteremiaCatheter-Related InfectionsDouble-Blind MethodEquivalence Trials as TopicFemaleHealth Care CostsHealth ResourcesHumansMaleMiddle AgedParenteral Nutrition, HomeSaline SolutionTaurineThiadiazinesSaline SolutionTaurinetaurolidineThiadiazines

Identifiers

PMID29978597
PMCPMC6099431
OpenAlexW2846676492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.